Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12233077 | 0.87 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL26246724 | 0.77 | SMN1; SMN2 (0.41) | ALDH1A1L3MBTL1KDM4EKMT2APKM | |
| SCHEMBL410293 | 0.77 | KMT2A (0.45) | ALDH1A1KMOKDM4EKMT2APKM | |
| SCHEMBL12541924 | 0.75 | L3MBTL1 (0.32) | L3MBTL1KDM4EKMT2APKMCCR5 | |
| SCHEMBL21938463 | 0.75 | POLB (0.42) | KDM4EKMT2APKM | |
| SCHEMBL26315353 | 0.73 | — | — | |
| SCHEMBL20061357 | 0.73 | KMT2A (0.36) | ALDH1A1L3MBTL1KDM4EKMT2APKM | |
| SCHEMBL16984947 | 0.73 | ALDH1A1 (0.46) | ALDH1A1KMOKDM4EKMT2APKM | |
| SCHEMBL31289794 | 0.73 | KMO (0.33) | ALDH1A1KMOKDM4EKMT2A | |
| SCHEMBL411769 | 0.73 | ITGB1 (0.36) | ALDH1A1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065397-A1 | PREPARATION OF KETONE AMIDES | Scherimg Corporation (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120065397-A1 | PREPARATION OF KETONE AMIDES | Scherimg Corporation (US) | 2012-03-15 | — | — | US | disclosed |
| US-7759487-B2 | Preparation of ketone amides | SCHERING CORPORATION (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759487-B2 | Preparation of ketone amides | SCHERING CORPORATION (US) | 2010-07-20 | — | — | US | disclosed |
| US-7714018-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100029939-A1 | PREPARATION OF KETONE AMIDES | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-20100029939-A1 | PREPARATION OF KETONE AMIDES | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| EP-1761542-B1 | OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | disclosed |
| CN-101001860-A | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (CH) | 2007-07-18 | — | — | CN | disclosed |
| US-20070117859-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-05-24 | — | — | US | disclosed |
| EP-1761542-A2 | OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| US-7164019-B2 | Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC | ROCHE PALO ALTO LLC (US) | 2007-01-16 | — | — | US | disclosed |
| US-20060014767-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-01-19 | — | — | US | disclosed |
| WO-2005121145-A2 | OCTAHYDRO-PYRROLO[3,4-C] DERIVATIVES AND THEIR USE AS ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029939-A1 | PREPARATION OF KETONE AMIDES | CCR5, CCR2, ACKR3 | ALDH1A1 603/4885L3MBTL1 4525/4885KMO 203/4885 |
| US-20060014767-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | ALDH1A1 1773/4885L3MBTL1 4488/4885KMO 827/4885 |
| US-20120065397-A1 | PREPARATION OF KETONE AMIDES | CCR5, CCR2, ACKR3 | ALDH1A1 603/4885L3MBTL1 4525/4885KMO 203/4885 |
| US-20070117859-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | ALDH1A1 1773/4885L3MBTL1 4488/4885KMO 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.